Breast Cancer
From the Journals
Higher risk of death with endocrine therapy nonadherence
“Importantly, improving adherence and persistence represents a low-hanging fruit for increasing survival in luminal breast cancer.”
From the Journals
PET-CT scans move more women with LABC up to stage IV
The results of a new study comparing the use of PET-CT with conventional methods for staging locally advanced breast cancer has already changed...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
From the Journals
Breast cancer family history linked to better BC survival
A family history of breast cancer was associated with a lower risk of breast cancer-specific death, after adjustments, a new study finds.
Latest News
T-DXd active in many solid tumors; ‘shift in thinking’
T-DXd is a potential new treatment option for patients with HER2-expressing solid tumors, experts say.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
From the Journals
Low-carb, plant-rich diets tied to breast cancer survival?
“Breast cancer survivors could benefit from limiting intake of carbohydrates, especially from fruit juice, sugar-sweetened beverages, and added...
News for Your Practice
News & Perspectives from Ob.Gyn. News
NEWS FROM THE FDA/CDC
New USPSTF draft suggests mammography start at 40, not 50
...
Conference Coverage
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
Latest News
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.